Earmark - Cancer Vaccine (Note: only for continued development of molecular switching vaccines using genetically modified Listera for cancer, infectious diseases and bio-defense)

Agency:		Department of Defense--Military
Bureau:		Research, Development, Test, and Evaluation
Account:		Research, development, test, and evaluation, Army (21-2040)
Certifying Official:		Deputy Comptroller Program/Budget
Contact Information:		http://WWW.DOD.GOV 703-697-5131

Cancer Vaccine (Note: only for continued development of molecular switching vaccines using genetically modified Listera for cancer, infectious diseases and bio-defense)

1 recipient will receive $3,257,000. This is a continuing earmark.

Year Enacted: 2005

Description: Cancer Vaccine (for Continued Development of Molecular Switching Vaccines Using Genetically Modified Listeria for Cancer, Infectious Disease and Bio-Defense); FY05 DoD Appropriations Conference Report 108-622, page 257, Cancer Vaccine $3,400,000

Beneficiary/Recipient	Amount ($K)	Program	Type	Address
Cerus Corporation	$3,257		For-Profit	Concord, CA

Citation

Source: Appropriations Report Language - Conference

Reference: 108-622

Location: Line 31, Page 257

Citation Excerpt: Cancer Vaccine (Note: only for continued development of molecular switching vaccines using genetically modified Listera for cancer, infectious diseases and bio-defense)

Last Modified: 16-Apr-2007